Safety and Survival Data Presented From CIRT-EU Registry of Sirtex SIR-Spheres Therapy
September 15, 2020—Sirtex Medical announced that new real-world data on safety and overall survival for the company’s targeted liver cancer therapy, SIR-Spheres Y-90 resin microspheres, was presented for the first time at the Cardiovascular and Interventional Radiological Society of Europe’s CIRSE 2020 Summit held online September 12-15.
NASIR-HCC Study Evaluates Nivolumab Use Following Sirtex Medical’s SIRT to Treat Liver Cancer
September 14, 2020—Sirtex Medical announced that positive trial data from the NASIR-HCC study of hepatocellular carcinoma (HCC) treatment were reported by principal investigator Professor Bruno Sangro, MD, at the International Liver Cancer Association’s ILCA 2020 virtual conference held online September 11-13.
Sirtex Medical Makes a Strategic Investment in Nanospectra Biosciences
September 8, 2020––Sirtex Medical, the global health care company focused on targeted therapies to treat liver cancer, announced a lead and strategic investment in Nanospectra Biosciences, Inc., which is developing nanomedicine for selective thermal ablation.
Sirtex Completes Enrollment of United States RESiN Registry
August 24, 2020—Sirtex Medical US Holdings, Inc. announced that enrollment in the United States RESiN Registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for a satisfactory number of patients enrolled for meaningful data analysis.
Sirtex Medical Launches the Siros System for Delivery of SIR-Spheres in Liver Cancer Treatment
August 3, 2020—Sirtex Medical US Holdings, Inc. announced the launch of the Siros system for the delivery of the company’s SIR-Spheres yttrium-90 resin microspheres in the targeted treatment of liver cancer.
Siemens Healthineers Plans to Acquire Varian for $16.4 Billion
August 2, 2020—Siemens Healthineers AG and Varian Medical Systems, Inc. announced an agreement for Siemens Healthineers to acquire all shares of Varian for $177.50 per share in cash, corresponding to a purchase price of approximately $16.4 billion.
Terumo Acquires Quirem Medical
July 15, 2020—Terumo Corporation announced it has completed the acquisition of Quirem Medical BV, a Netherlands-based health care startup specializing in next-generation microspheres for selective internal radiation therapy (SIRT) based on the radioactive isotope Holmium-166 to treat liver tumors.
Study Demonstrates Feasibility of Hologram Technology in Liver Tumor Ablation
June 14, 2020—Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to research presented during a virtual session of the Society of Interventional Radiology's (SIR) 2020 annual scientific meeting held June 13-14.
Transarterial Chemoperfusion Studied for Treating Mesothelioma
June 14, 2020—The Society of Interventional Radiology (SIR) announced the presentation of research showing that transarterial chemoperfusion as a treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options.
Guerbet's Lipiodol Ultra-Fluid Approved in China for cTACE
June 9, 2020—Guerbet announced that the China National Medical Products Administration has approved an additional indication for Lipiodol Ultra-Fluid for use in conventional transarterial chemoembolization (cTACE) for adult patients with intermediate-stage hepatocellular carcinoma (HCC) in the People's Republic of China.
Sirtex Medical Appoints Dr. Mark Turco as Global Chief Medical Officer
June 3, 2020––Sirtex Medical US Holdings, Inc. announced the appointment of Mark A. Turco, MD, as Global Chief Medical Officer and Executive Vice President of Research & Development, effective June 1, 2020. Sirtex is focused on targeted radiation therapies for liver cancer, including SIR-Spheres yttrium-90 resin microspheres. The company has global headquarters in Woburn, Massachusetts.
Yttrium-90 Radioembolization Analyzed in Patients With Intrahepatic Cholangiocarcinoma
May 28, 2020—In Journal of Vascular and Interventional Radiology (JVIR), Stefan Buettner, MD, et al reported observational data of treatment outcomes of yttrium-90 (Y-90) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma.
Austrian Study Supports Simultaneous Stereotactic RF Ablation to Manage Multiple Liver Tumors
May 20, 2020—Simultaneous stereotactic radiofrequency ablation (SRFA) was shown to be a “feasible, safe, and efficacious option” for the simultaneous management of multiple primary and metastatic liver tumors in a study by Peter Schullian, MD, et al published in the June edition of Journal of Vascular and Interventional Radiology (JVIR; 2020;31:943–952).
Guerbet’s Vectorio Kit Approved in Canada for Interventional Oncology Procedures
May 19, 2020—Guerbet announced the registration in Canada of Vectorio, a kit for imaging of hepatocellular carcinoma (HCC) that provides a set of Lipiodol (Guerbet)-resistant medical devices, including patented syringes, stopcock, and sampling devices.
Study Suggests Need for Cautious Patient Selection to Treat HCC With Y-90 Radioembolization
May 1, 2020—Findings from an evaluation of yttrium-90 (Y-90) radioembolization outcomes across Child-Pugh scores in patients with advanced hepatocellular carcinoma (HCC), per the Barcelona Clinic Liver Cancer (BCLC) staging system, were published by Qingquan Zu, MD, et al in CardioVascular and Interventional Radiology (CVIR; 2020;43:721–731).
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.